Theriva Biologics Inc (TOVX)
0.236
+0.01
(+2.61%)
USD |
NYAM |
Jul 05, 16:00
0.236
0.00 (0.00%)
After-Hours: 16:25
Theriva Biologics SG&A Expense (Annual): 7.12M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.12M |
| December 31, 2022 | 9.858M |
| December 31, 2021 | 6.474M |
| December 31, 2020 | 5.029M |
| December 31, 2019 | 4.58M |
| December 31, 2018 | 5.727M |
| December 31, 2017 | 7.467M |
| December 31, 2016 | 10.14M |
| December 31, 2015 | 8.074M |
| December 31, 2014 | 6.013M |
| December 31, 2013 | 5.832M |
| December 31, 2012 | 5.012M |
| December 31, 2011 | 2.588M |
| December 31, 2010 | 2.117M |
| December 31, 2009 | 2.709M |
| Date | Value |
|---|---|
| December 31, 2008 | 2.676M |
| December 31, 2007 | 3.811M |
| December 31, 2006 | 1.439M |
| December 31, 2005 | 0.2857M |
| December 31, 2002 | 4.482M |
| December 31, 2001 | 4.552M |
| December 31, 2000 | 2.818M |
| December 31, 1999 | 2.277M |
| December 31, 1998 | 3.00M |
| December 31, 1997 | 4.60M |
| December 31, 1996 | 7.70M |
| December 31, 1995 | 3.00M |
| December 31, 1994 | 6.40M |
| December 31, 1993 | 3.60M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
4.58M
Minimum
2019
9.858M
Maximum
2022
6.612M
Average
6.474M
Median
2021
SG&A Expense (Annual) Benchmarks
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 15.29M |
| iBio Inc | 19.02M |
| Oragenics Inc | 5.452M |
| Nanoviricides Inc | 2.551M |